Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 15,619 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin and Connective Tissue Disease Clear all

Conditions: Stage 0 Skin Melanoma, Stage I Skin Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage II Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage III Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions: Internet-Based Intervention, Questionnaire Administration, Survey Administration; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Charlottesville, Virginia

Conditions: Breast Cancer, Muscle Fatigue
Interventions: Pioglitazone 15mg, Pioglitazone 30 mg; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Breast Cancer, Breast Tumors, Breast Neoplasms
Interventions: Decitabine, LBH589, Tamoxifen; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ovarian Diseases, Ovarian Neoplasms
Interventions: Laboratory Tumor Marker Analysis, Transvaginal Ultrasound, Health Status Questionnaire; Other
Lead sponsor: Swedish Medical Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 534 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions: abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Months to 80 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: La Jolla, California • Denver, Colorado • Chicago, Illinois + 3 more

Conditions: Plaque Psoriasis, Psoriasis, Skin Diseases
Interventions: JTE-451 Tablets, Placebo Tablets; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Santa Monica, California • Temecula, California • Indianapolis, Indiana + 3 more

Conditions: Rheumatoid Arthritis, Pharmacokinetics of ASP2409
Interventions: ASP2409, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: Anniston, Alabama • Costa Mesa, California • Clearwater, Florida + 7 more

Conditions: Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II), Mucopolysaccharidosis Type III (MPS III), Mucopolysaccharidosis Type VI (MPS VI), Krabbe Disease
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 1 Day to 18 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 3
States / cities: Chicago, Illinois • Minneapolis, Minnesota • Buffalo, New York

Conditions: Melanoma
Interventions: TNFerade™; Drug
Lead sponsor: GenVec; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions: Atorvastatin and Lisinopril, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: HER2Bi-armed activated T cells, Cyclophosphamide, Laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer Female, Sexual Dysfunction
Interventions: Educational video series; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Metastatic Breast Cancer
Interventions: GTx-024 9mg; Drug
Lead sponsor: GTx; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Miami, Florida • Peoria, Illinois • Boston, Massachusetts + 1 more

Conditions: Metastatic Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: ziv-aflibercept; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Dapagliflozin 10Mg Tab; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions: Stem Cell Transplantation, CD34 selection; Procedure · Device
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Melanoma, Metastatic Melanoma, Solid Tumor, Neoplasm
Interventions: MLN2480; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 9
States / cities: San Francisco, California • Denver, Colorado • Augusta, Georgia + 6 more

Conditions: HIV, HIV Lipodystrophy
Interventions: tesamorelin, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acne Vulgaris on the Face
Interventions: DispersinB Acne Cleanser; Device
Lead sponsor: Kane Biotech Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: Anthracycline based chemotherapy, taxane-based chemotherapy; Drug
Lead sponsor: Jenny C. Chang, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: bevacizumab, paclitaxel albumin-stabilized nanoparticle formulation; Biological · Drug
Lead sponsor: Premiere Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Breast Cancer
Interventions: brachytherapy; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Uterine Fibroids
Interventions: MR-HIFU treatment, Sham treatment; Device
Lead sponsor: Philips Healthcare; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 7
States / cities: Chicago, Illinois • Ann Arbor, Michigan • The Bronx, New York + 4 more

Search by objective public record fields.

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

Re-expression of ER in Triple Negative Breast Cancers

Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children

TNFerade™ Biologic Plus Radiation for Metastatic Melanoma

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer

Sexual Health and Breast Cancer: Developing Appropriate Education for Women Going Through Treatment

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

VEGF Trap in Treating Patients With Metastatic Breast Cancer

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Effects of Growth Hormone Releasing Hormone in HIV

Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer

Multi-catheter High Dose Rate (HDR) Breast Brachytherapy

Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids